Skip to Content

  • Search

View Additional Section Content

229G - A Phase II Evaluation of Combination Bevacizumab(NCI Supplied Agent:NSC704865, IND 7921) and Temsirolimus (CCI-779, NCI Supplied Agent,NSC683864,IND 61010) in the Treatment of Recurrent or Persistent Endomet Carcinoma

Clinical Trial Categories

  • Corpus Uterus/Endometrial Cancer
Hanjani Institute for Gynecologic Oncology at 215-885-0220


  • Hanjani Institute for Gynecologic Oncology
    The Rosenfeld Cancer Center
    1200 Old York Rd, AMH - 1 Widener
    Abington, PA 19001
    Office: 215-885-0220
    Fax: 215-576-0740

Find a Physician
Search Our Directory


Schedule a Test
Request an Appointment


Clinical Trials Details